1. Home
  2. GENK vs ACXP Comparison

GENK vs ACXP Comparison

Compare GENK & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GEN Restaurant Group Inc.

GENK

GEN Restaurant Group Inc.

HOLD

Current Price

$1.67

Market Cap

12.8M

ML Signal

HOLD

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

SELL

Current Price

$1.17

Market Cap

6.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
GENK
ACXP
Founded
2011
2017
Country
United States
United States
Employees
2700
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.8M
6.2M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
GENK
ACXP
Price
$1.67
$1.17
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $17.00
AVG Volume (30 Days)
★ 2.0M
86.9K
Earning Date
11-06-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 62.50
N/A
EPS
★ N/A
N/A
Revenue
★ $208,380,000.00
N/A
Revenue This Year
$2.05
N/A
Revenue Next Year
$4.89
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 15.12
N/A
52 Week Low
$1.39
$1.15
52 Week High
$3.20
$7.54

Technical Indicators

Market Signals
Indicator
GENK
ACXP
Relative Strength Index (RSI) 51.31 32.66
Support Level $1.56 N/A
Resistance Level $1.80 $1.75
Average True Range (ATR) 0.19 0.06
MACD 0.01 -0.01
Stochastic Oscillator 27.51 10.87

Price Performance

Historical Comparison
GENK
ACXP

About GENK GEN Restaurant Group Inc.

GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: